Alkem Laboratories

Alkem Laboratories ROE

The Return on Equity (ROE) of Alkem Laboratories (ALKEM.NS) as of Nov 11, 2026 is 16.66 %. In the previous year, Return on Equity (ROE) was 18.07 % — a change of -7.82% (lower).

ROE

16.66 %

YoY

-7.82%

Last updated:

In 2026, Alkem Laboratories's return on equity (ROE) was 16.66 %, a -7.82% increase from the 18.07 % ROE in the previous year.

The Alkem Laboratories ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
13.98 INR
Jan 1, 2020
18.29 INR
Jan 1, 2021
21.49 INR
Jan 1, 2022
19.05 INR
Jan 1, 2023
10.88 INR
Jan 1, 2024
17.41 INR
Jan 1, 2025
18.07 INR
Jan 1, 2026
16.66 INR
The Alkem Laboratories ROE history
YEARROEYoY
16.66 %-7.82%
18.07 %+3.76%
17.41 %+60.05%
10.88 %-42.89%
19.05 %-11.34%
21.49 %+17.45%
18.29 %+30.85%
13.98 %+7.78%
12.97 %-35.03%
19.97 %-0.60%
20.09 %+53.84%
13.06 %-21.03%
16.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

ROE Details

Decoding Alkem Laboratories's Return on Equity (ROE)

Alkem Laboratories's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Alkem Laboratories's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Alkem Laboratories's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Alkem Laboratories’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Alkem Laboratories stock

Return on Equity (ROE) of Alkem Laboratories is 16.66 % in 2026.

Return on Equity (ROE) of Alkem Laboratories changed from 18.07 % to 16.66 %, representing a -7.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Alkem Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Alkem Laboratories

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Alkem Laboratories